WebJul 22, 2024 · Roche is developing a drug to treat Alzheimer's disease. ... that the company was engaged in talks with the FDA about possibly accelerating approval of its Alzheimer’s drug candidate, gantenerumab.
Your application Roche
WebJun 30, 2024 · Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Atea’s purine nucleotide prodrug platform. The interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with COVID-19 of which data from 62 patients were evaluable for virology analysis. WebWe’re passionate about improving patients’ lives and creating healthier communities for all. We foster a culture of inclusivity, integrity and creativity while boldly pursuing answers to … the view restaurant prices
Roche Schizophrenia Candidate Fails Two Phase III Trials
WebApply for Sr. Principal Scientist, Computational Chemistry - Small Molecule Drug Discovery job with Genentech in South San Francisco, California, United States of America. Research & Development at Genentech WebMar 4, 2024 · The Roche Phase 2 trial ( NCT04225715) is a randomized, adaptive, open-label platform trial designed to evaluate the safety, tolerability and efficacy of multiple combinations of novel agents in... WebJun 2, 2024 · Roche’s deep oncology pipeline is adding a drug candidate from Repare Therapeutics that works by interfering with a DNA repair mechanism of cancer cells. Repare receives $125 million up front ... the view restaurant patchogue